4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $42.13 Consensus Price Target from Analysts

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has earned a consensus rating of “Moderate Buy” from the ten brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $42.13.

Several research analysts have weighed in on FDMT shares. Chardan Capital reiterated a “buy” rating and issued a $39.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. Leerink Partners reiterated an “outperform” rating and issued a $36.00 price objective (down previously from $40.00) on shares of 4D Molecular Therapeutics in a research note on Thursday, September 19th. Morgan Stanley started coverage on shares of 4D Molecular Therapeutics in a research note on Thursday, November 21st. They issued an “underweight” rating and a $8.00 price objective on the stock. Cantor Fitzgerald lowered shares of 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, September 23rd. Finally, HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th.

Institutional Trading of 4D Molecular Therapeutics

Large investors have recently modified their holdings of the company. nVerses Capital LLC bought a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter worth $40,000. Values First Advisors Inc. bought a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter worth $57,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of 4D Molecular Therapeutics by 64.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock worth $108,000 after buying an additional 3,922 shares during the period. Proficio Capital Partners LLC bought a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter worth $108,000. Finally, Quest Partners LLC boosted its holdings in 4D Molecular Therapeutics by 17,409.1% in the 2nd quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock valued at $121,000 after purchasing an additional 5,745 shares during the period. 99.27% of the stock is owned by institutional investors.

4D Molecular Therapeutics Stock Performance

4D Molecular Therapeutics stock opened at $7.18 on Friday. The firm has a market cap of $331.93 million, a PE ratio of -2.62 and a beta of 2.75. The firm’s 50 day moving average price is $8.43 and its two-hundred day moving average price is $15.10. 4D Molecular Therapeutics has a twelve month low of $6.77 and a twelve month high of $36.25.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.